New chemo cocktail shows promise in shrinking breast tumors before surgery

NCT ID NCT00295893

Ongoing Disease control Sponsor: City of Hope Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tested two different chemotherapy regimens, with or without the targeted drug trastuzumab, given before surgery to patients with stage II or III breast cancer. The goal was to see which combination better eliminated cancer cells in the breast and lymph nodes. A total of 121 participants received either TAC (docetaxel, adriamycin, cytoxan) or AC followed by Abraxane and carboplatin, with some also getting trastuzumab. The main measure of success was whether no cancer remained after treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: combination chemotherapy (docetaxel, doxorubicin, cyclophosphamide, paclitaxel, carboplatin) with or without trastuzumab
What this could lead to: If successful, this could help identify which chemo combination works best before surgery to shrink breast tumors and improve outcomes.
What could go wrong: This is a small, early-phase trial (121 participants) with no long-term results yet. The benefits seen may not apply to all breast cancer types or stages.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast ductal adenocarcinoma breast neoplasm Carcinoma, Lobular inflammatory breast carcinoma male breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Locations

City of Hope Medical Center

Duarte, California, 91010-3000, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.